Table 1.
Participant characteristics
| AERD [n = 240] | ATA [n = 226] |
Control [n = 71] |
p-value (ANOVA) |
T-Test | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age (yrs) | 49.3 [0.8] | 49.7 [1.0] | 44.3 [1.6] | 0.008 | |
| Gender [M/F] | 74/166 | 68/158 | 35/36 | 0.007 | |
| BMI (kg/m2) | 26.7 [0.3] | 27.1 [0.4] | 25.6 [1.0] | ||
| Duration of asthma (yrs) | 18.8 [0.8] | 15.2 [1.0] | n/a | < 0.0001 | |
| ACT; uncontrolled, n [%] | 108 [46] | 98 [46] | n/a | ||
| Medication use | |||||
| High dose ICS/Oral CS, n (%) | 63 (26) | 37 (18) | n/a | 0.03 | |
| High dose ICS > 500 (μg/d), n (%) | 62 (26) | 52 (25.5) | n/a | ||
| Low dose ICS ≤500 (μg/d), n (%) | 78 (33) | 92 (44.7) | n/a | 0.008 | |
| No ICS or Oral CS, n (%) | 3 (14) | 25 (12.4) | n/a | ||
| Lung functions | |||||
| FEV1% predicted | 79.8 [1.3] | 86.6 [1.4] | n/a | 0.0003 | |
| FEV1 %FVC | 68.8 [0.7] | 74.8 [0.7] | n/a | < 0.0001 | |
Mean (SEM); Definition of abbreviations: AERD Aspirin-Exacerbated Respiratory Disease, ATA Aspirin Tolerant Asthma, M Male, F Female, BMI Body mass index, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, CS Corticosteroidsm, ICS Inhaled Corticosteroids